Catastrophic cardiovascular adverse reactions to protamine are nitric oxide/cyclic guanosine monophosphate dependent and endothelium mediated: Should methylene blue be the treatment of choice?

Chest

Volumn 122, Issue 3, 2002, Pages 1061-1066

  Viaro, Fernanda ^a   Dalio, Marcelo B ^a   Evora, Paulo Roberto B ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Anaphylaxis; Cardiopulmonary bypass; Endothelium; Heparin; Nitric oxide; Protamine

Indexed keywords

CYCLIC GMP; HEPARIN; METHYLENE BLUE; NITRIC OXIDE; NITRIC OXIDE SYNTHASE INHIBITOR; OXYGEN; PROTAMINE;

ACCURACY; ANAPHYLAXIS; ANESTHESIA INDUCTION; BLOOD PRESSURE; CARDIOPULMONARY BYPASS; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CONDUCTANCE; CORONARY ARTERY DILATATION; ENDOTHELIUM; HEART MUSCLE OXYGEN CONSUMPTION; HEART OUTPUT; HEART RATE; HEMODYNAMICS; HUMAN; HYPERPOLARIZATION; HYPOTENSION; IN VITRO STUDY; INFUSION; LUNG ARTERY PRESSURE; LUNG CIRCULATION; LUNG VASOCONSTRICTION; MICROVASCULATURE; NONHUMAN; PRIORITY JOURNAL; PROSPECTIVE STUDY; REVIEW; SHOCK; SYSTEMIC VASCULAR RESISTANCE; UNITED STATES; VASODILATATION;

EID: 0036382855     PISSN: 00123692     EISSN: None     Source Type: Journal    
DOI: 10.1378/chest.122.3.1061     Document Type: Article

References (34)

1. Shapira N, Schaff HV, Piehler JM, et al. Cardiovascular effects of protamine sulfate in man. Thorac Cardiovasc Surg 1982; 84:505-514
2. Masone R, Oka Y, Hong Y, et al. Cardiovascular effects of right atrial injection of protamine sulfate as compared to left atrial injection [abstract]. Anesthesiology 1982; 57:A6
3. Milne B, Rogers K, Cervenko F, et al. The hemodynamic effects of intraaortic vs intravenous administration of protamine for reversal of heparin in man. Can Anaesth Soc J 1983; 30:347-351
4. Marin-Neto JA, Sykes MK, Marin JLB, et al. Effect of heparin and protamine on left ventricular performance in the dog. Cardiovasc Res 1979; 13:254-259
5. Lowenstein E, Johnston WE, Lappas DG, et al. Catastrophic pulmonary vasoconstriction associated with protamine reversal of heparin. Anesthesiology 1983; 59:470-473
6. Horrow JC. Protamine: a review of its toxicity. Anesth Analg 1985; 64:348-361
7. Jaques LB. A study of the toxicity of the protamine salmine. Br J Pharmacol 1949; 4:135-144
8. Jones MM, Hill AB, Nahrwold ML, et al. Effect of protamine on plasma ionized calcium in the dog. Can Anaesth Soc 1982; J29:65-67
9. Frater RMW, Oka Y, Hong Y, et al. Protamine-induced circulatory changes. Thorac Cardiovasc Surg 1984; 87:687-692
10. Wakefield TW, Hantler CB, Lindblad B, et al. Protamine pretreatment attenuation of hemodynamic and hematologic effects of heparin-protamine interaction. J Vasc Surg 1986; 3:885-889
11. Stewart WJ, McSweeney SM, Kellett MA, et al. Increased risk of severe protamine reactions in NPH insulin-dependent diabetics undergoing cardiac catheterization. Circulation 1984; 70:788-792
12. Degges RD, Foster ME, Kirklin JK, et al. Effects of protamine administration after cardiopulmonary bypass on complement, blood elements, and hemodynamic state. Ann Thorac Surg 1986; 41:193-199
13. Horrow JC. Protamine: a review of its toxicity. Anesth Analg 1985; 64:348-361
14. Hines RL, Barash PG. Protamine: does it alter right ventricular function? Anesth Analg 1986; 65:1271-1274
15. Pearson PJ, Evora PR, Ayrancioglu K, et al. Protamine releases endothelium-derived relaxing factor from systemic arteries: a possible mechanism of hypotension during heparin neutralization. Circulation 1992; 86:289-294
16. Ando T, Yamasaki M, Suzuki K. Protamines. In: Kleinzeller A, Springer GF, Wittmann HG, eds. Molecular biology, biochemistry and biophysics (vol 12). Berlin, Germany: Springer-Verlag, 1973; 1-30
17. Rees DD, Palmer RMJ, Hodson HF, et al. A specific inhibitor of nitric oxide formation from L-arginine attenuates endothelium-dependent relaxation. Br J Pharmacol 1989; 96:418-424
18. Pearson PJ, Evora PRB, Schaff HV. Endothelium-dependent relaxation to poly-L-arginine: lack of inhibition by blockers of nitric oxide synthesis of action. Circulation 84(suppl II):II674
19. Evora PR, Pearson PJ, Schaff HV. Protamine induces endothelium-dependent vasodilation of the pulmonary artery. Ann Thorac Surg.1995; 60:405-410
20. Palmer PMJ, Rees DD, Ashton DS, et al. L-arginine is the physiological precursor for the formation of nitric oxide in endothelium-dependent relaxation. Biochem Biophys Res Comm 1988; 153:1251-1256
21. Thomas G, Mostaghim R, Ramwell PW. Endothelium-dependent vascular relaxation by arginine containing polypeptides. Biochem Biophys Res Comm 1986; 141: 446-451
22. Schumacher WA, Heran CL, Ogletree ML. Effect of thromboxane receptor antagonism on pulmonary hypertension caused by protamine-heparin interactions in pigs. Circulation 1988; 78(suppl):II-207
23. Pearson PJ, Schaff HV, Vanhoutte PM. Long-term impairment of endothelium-dependent relaxations to aggregating platelets after reperfusion injury in canine coronary arteries. Circulation 1990; 81:121-127
24. Pearson PJ, Schaff HV, Vanhoutte PM. Acute impairment of endothelium-dependent relaxations to aggregating platelets following reperfusion injury in canine coronary arteries. Circ Res 1990; 67:385-393
25. Castresana MR, Zhang LM, Newman WH. Protamine does not affect the formation of cGMP or cAMP in pig vascular smooth muscle cells in response to vasodilators. Crit Care Med 1995; 23:939-943
26. Eichinger MR, Walker BR. Nitric oxide and cGMP do not affect fluid flux in isolated rat lungs. J Appl Physiol 1996; 80:69-76
27. Fratacci MD, Frostell CG, Chen TY, et al. Inhaled nitric oxide: a selective pulmonary vasodilator of heparin-protamine vasoconstriction in sheep. Anesthesiology 1991; 75:990-999
28. Raikar GV, Hisamochi K, Raikar BL, et al. Nitric oxide inhibition attenuates systemic hypotension produced by protamine. Thorac Cardiovasc Surg 1996; 111:1240-1246
29. Cable DG, Sorajja P, Oeltjen MR, et al. Different effects of protamine on canine coronary microvessel and conductance arteries: evidence of hyperpolarizing factor release. Surgery 1999; 126:835-841
30. Yiu P, Robin J, Pattison C. Reversal of refractory hypotension with single-dose methylene blue after coronary artery bypass surgery. Thorac Cardiovasc Surg 1999; 118:195-196
31. Andrade JCS, Batista Filho ML, Evora PRB, et al. Methylene blue administration in the treatment of the vasoplegic syndrome after cardiac surgery. Rev Bras Circ Cardiovasc 1996; 11:107-114
32. Evora PRB, Ribeiro PJF, Andrade JCS. Methylene blue administration in SIRS after cardiac operations [letter]. Ann Thorac Surg 1997; 63:112-113
33. Evora PRB. Should methylene blue be the drug of choice to treat vasoplegias caused by cardiopulmonary bypass and anaphylactic shock [letter]? Thorac Cardiovasc Surg 2000; 119:633-634
34. Evora PRB, Roselino CH, Schiavetto PM. Methylene blue in anaphylactic shock [letter]. Ann Emerg Med 1997; 30:240